Xolair

Xolair (omalizumab) is a prescription medication used to help control allergic asthma and chronic hives. It works by targeting and blocking immunoglobulin E (IgE) to reduce allergic reactions. This injectable therapy is designed for long-term management of persistent symptoms. Suitable for adults and adolescents.

Xolair is commonly used to treat moderate to severe persistent allergic asthma in patients whose symptoms are not adequately controlled by inhaled corticosteroids. It is also prescribed for chronic spontaneous urticaria (hives) in adults and adolescents who continue to experience symptoms despite antihistamine treatment. Xolair helps reduce the frequency and severity of asthma attacks and hive flare-ups by targeting the underlying allergic response.

Xolair works gradually to reduce allergic reactions by binding to IgE antibodies, which play a key role in triggering allergy symptoms. Patients may notice a decrease in the frequency of asthma attacks or hive outbreaks over time. Regular use is important to maintain its effects, and individual responses can vary.

Xolair should be administered under medical supervision, typically in a healthcare setting. Patients with a history of severe allergic reactions to omalizumab or any of its components should avoid this medication. It is important to inform your healthcare provider about all current medications and medical conditions before starting treatment.

Xolair has a low potential for drug interactions due to its targeted mechanism of action. However, it is always important to discuss all medications with your healthcare provider, including over-the-counter drugs and supplements. No specific interactions have been widely reported, but caution is advised when combining with other therapies for asthma or hives.